Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study

被引：0
|
作者：
Lee, Samuel S. [1 ]
Kilvert, Leah [1 ]
Liu, Hongqun [1 ]
Trepanier, Janie [2 ]
机构：
[1] Univ Calgary, Liver Unit, Calgary, AB, Canada
[2] Merck Canada, Montreal, PQ, Canada
来源：
DIGESTIVE AND LIVER DISEASE | 2016年 / 48卷 / 03期
关键词：
D O I：
10.1016/j.dld.2015.08.015
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：344 / 344
页数：1
相关论文
共 50 条
  • [1] HCV genotype 2 and 3 infections:: what is the optimal duration for peginterferon α-2b and ribavirin therapy?
    Muir, AJ
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (12): : 568 - 569
  • [2] HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon α-2b and ribavirin therapy?
    Andrew J Muir
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 : 568 - 569
  • [3] OVERALL SAFETY PROFILE OF BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN IN GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN
    Flamm, Steven L.
    Lawitz, Eric
    Jacobson, Ira M.
    Bourliere, Marc
    Hezode, Christophe
    Vierling, John M.
    Niederau, Claus
    Sherman, Morris
    Bacon, Bruce R.
    Pedicone, Lisa
    Goteti, Venkata S.
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Poordad, F. Fred
    HEPATOLOGY, 2011, 54 : 838A - 838A
  • [4] RESPONSE GUIDED THERAPY BY PEGINTERFERON A2B PLUS RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 2
    Yamaguchi, Y.
    Tamori, A.
    Tanaka, Y.
    Iwai, S.
    Kobayashi, S.
    Fujii, H.
    Morikawa, H.
    Hagihara, A.
    Enomoto, M.
    Kawada, N.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S462 - S462
  • [5] Efficacy among North American and European HCV genotype-1 treatment-naive and previous non-responders and relapsers to peginterferon/ribavirin when treated with boceprevir plus peginterferon alfa-2b/ribavirin
    Bognar, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 97 - 98
  • [6] EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
    Marcellin, P.
    Vierling, J. M.
    Alric, L.
    Pirisi, M.
    Tran, A.
    Albrecht, J. K.
    Brass, C. A.
    Boparai, N.
    Sniukiene, V.
    Burroughs, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S184 - S184
  • [7] ANALYSIS OF SUSTAINED VIRAL RESPONSE AND BOCEPREVIR RESISTANCE FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV GENOTYPE 1 PRIOR RELAPSERS AND NON-RESPONDERS
    Howe, John A.
    Ogert, Robert A.
    Barnard, Richard J.
    Hazuda, Dada
    Pedicone, Lisa
    Brass, Clifford A.
    Albrecht, Janice K.
    Flamm, Steven L.
    HEPATOLOGY, 2011, 54 : 443A - 443A
  • [8] Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection?
    Eva Herrmann
    Stefan Zeuzem
    Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 : 362 - 363
  • [9] Efficacy Among North American and European HCV Genotype-1 Treatment-NaiVE and Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin
    Marcellin, Patrick
    Vierling, John M.
    Alric, Laurent
    Pirisi, Mario
    Tran, Albert
    Albrecht, Janice K.
    Brass, Clifford A.
    Boparai, Navdeep
    Sniukiene, Vilma
    Burroughs, Margaret
    GASTROENTEROLOGY, 2011, 140 (05) : S945 - S945
  • [10] Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection?
    Herrmann, Eva
    Zeuzem, Stefan
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2008, 5 (07): : 362 - 363
12345